Solifenacina zentiva 10 mg comprimidos recubiertos con pelicula efg

Do not takeSolifenacina Zentiva

• if you are allergic to solifenacina or any of the other ingredients of this medicine (listed in section 6).
• if you have difficulty urinating or emptying your bladder completely (urinary retention).
• if you have a severe stomach or intestinal disorder (including toxic megacolon, a complication associated with ulcerative colitis).
• if you have a muscle disease called myasthenia gravis, which can cause extreme weakness in certain muscles.
• if you have high eye pressure, with gradual loss of vision (glaucoma).
• if you are undergoing renal dialysis.
• if you have severe liver disease.
• if you have severe kidney disease or moderate liver disease and are being treated with medicines that can reduce the elimination of solifenacina from the body (e.g. ketoconazole). Your doctor or pharmacist will inform you if this is the case.

Warnings and precautions

Consult your doctor or pharmacist before starting to take this medicine:

• if you have problems emptying your bladder (=bladder obstruction) or urinating (e.g. weak urine flow). The risk of urine accumulation in the bladder (urinary retention) is much higher.
• if you have any obstruction of the digestive system (constipation).
• if you have an increased risk of decreased activity of the digestive system (gastrointestinal motility). Your doctor will inform you if this is the case.
• if you have severe kidney disease.
• if you have moderate liver disease.
• if you are being treated with medicines that can reduce the elimination of solifenacina from the body (e.g. ketoconazole).
• if you have hiatal hernia or heartburn.
• if you have a nervous disorder (autonomic neuropathy).

Inform your doctor before starting treatment with solifenacina, if any of the circumstances mentioned above have occurred at any time.

Before starting treatment with this medicine, your doctor will assess whether there are other causes for your need to urinate frequently (e.g. heart failure (insufficient heart pumping capacity) or kidney disease). If you have a urinary tract infection, your doctor will prescribe an antibiotic (a treatment for certain bacterial infections).

Children and adolescents

Solifenacina should not be used in children and adolescents under 18 years.

Taking Solifenacina Zentiva with other medicines

Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.

It is especially important to inform your doctor if you are taking:

• other anticholinergic medicines, the activity and adverse effects of both medicines may increase.
• cholinergic medicines as they may reduce the effect of solifenacina.
• medicines such as metoclopramide or cisapride, which make the digestive system work faster. Solifenacina may reduce their effect.
• medicines such as ketoconazole, ritonavir, nelfinavir, itraconazole, verapamil, and diltiazem, which reduce the elimination of solifenacina from the body.
• medicines such as rifampicin, phenytoin, and carbamazepine, which may increase the elimination of solifenacina from the body.
• medicines such as bisphosphonates, which may cause or worsen inflammation of the esophagus (esophagitis).

Taking Solifenacina Zentiva with food and drinks.

Solifenacina can be taken with or without food, as you prefer.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medicine.

You should not use this medicine if you are pregnant unless it is absolutely necessary.

You should not use this medicine during breastfeeding as solifenacina may pass into breast milk.

Driving and operating machines

Solifenacina may cause blurred vision and sometimes drowsiness or fatigue. If you experience any of these side effects, do not drive or operate machines.

Solifenacina Zentiva contains lactose monohydrate

If your doctor has told you that you have intolerance to some sugars, consult your doctor before taking this medicine.

Follow exactly the administration instructions for this medication as indicated by your doctor.This medication should be taken as directed by your doctor.If you are unsure, consult your doctor or pharmacist again.

The usual dose is 5 mg per day, unless your doctor tells you to take 10 mg per day. Try to take Solifenacina Zentiva every day at the same time.

This medication should be swallowed whole with some liquid. It can be taken with or without food, as you prefer. Do not crush the tablets.

Inform your doctor or pharmacist if you feel that the effect of solifenacina is too strong or too weak.

If you take moreSolifenacina Zentivathan you should

In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount used.

The symptoms of an overdose may include: headache, dry mouth, dizziness, drowsiness, and blurred vision, perception of things that are not there (hallucinations), pronounced excitement, convulsions, difficulty breathing, increased heart rate (tachycardia), urine accumulation in the bladder (urinary retention), and pupil dilation (mydriasis).

If you forgot to takeSolifenacina Zentiva

If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take the next dose. Never take more than one dose per day. If you have any doubts, consult your doctor or pharmacist at all times.

If you interrupt treatment withSolifenacina Zentiva

If you stop taking this medication, your overactive bladder symptoms may return or worsen. Consult your doctor at all times if you are thinking of interrupting treatment.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

Like all medicines, this medicine may cause side effects, although not everyone will experience them.

If you experience an allergic attack or a severe skin reaction (such as blistering and peeling of the skin), you must inform your doctor or pharmacist immediately.

Angioedema (allergy on the skin resulting in inflammation that occurs in the tissue beneath the skin surface) with respiratory tract obstruction (difficulty breathing) has been reported in some patients treated with solifenacin succinate. If angioedema appears, treatment with this medicine should be stopped immediately and appropriate treatment and/or measures should be taken.

Solifenacin Zentiva may cause the following side effects:

Very common(may affect more than 1 in 10 people):

• Dry mouth.

Common(may affect up to 1 in 10 people):

• Blurred vision.
• Constipation; nausea; indigestion with symptoms such as feeling of stomach heaviness, abdominal pain, belching, and stomach burning (dyspepsia), stomach discomfort.

Uncommon(may affect up to 1 in 100 people):

• Urinary tract infection; inflammation of the bladder (cystitis).
• Drowsiness; abnormal taste perception (dysgeusia).
• Dry eyes (irritated).
• Nasal dryness.
• Gastroesophageal reflux disease (reflux); dry throat.
• Dry skin.
• Difficulty urinating.
• Fatigue, Accumulation of fluid in the lower extremities (edema).

Rare(may affect up to 1 in 1,000 people):

• Dizziness, headache.
• Intestinal obstruction; accumulation of a large amount of hardened feces in the large intestine (fecal impaction).
• Vomiting.
• Itching, skin rash.
• Urinary retention due to inability to empty the bladder.

Very rare(may affect up to 1 in 10,000 people):

• Hallucinations; confusion.
• Allergic skin eruption.

Frequency not known(frequency cannot be estimated from available data):

• Decreased appetite; high levels of potassium in the blood that may cause an abnormal heart rhythm (hyperkalemia).
• Delirium.
• Increased pressure in the eyes (glaucoma).
• Irregular heartbeats (Torsade de Pointes); changes in heart electrical activity (ECG), palpitations, rapid heartbeat.
• Voice disorder (dysphonia).
• Intestinal blockage (ileus); abdominal discomfort.
• Liver disorder; abnormal liver tests.
• Erythema and skin peeling (dermatitis exfoliativa)
• Muscle weakness.
• Renal disorder
• Anaphylactic reaction

Reporting of side effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine

Keepthis medicationout of the sight and reach of children.

Do not usethis medicationafter the expiration date that appears on the blister pack and onthe box after CAD. The expiration date is the last day of the month indicated.

Store in the original packaging to protect it from light.

Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGREcollection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.

Composition ofSolifenacina Zentiva

• The active ingredientissuccinato de solifenacina.

Solifenacina Zentiva10 mg: Each tablet contains 10 mg of succinato de solifenacina corresponding to 7.5 mg of solifenacina.

• The other ingredients are:

Tablet core: Pregelatinized cornstarch; lactose monohydrate; microcrystalline cellulose; hypromellose; magnesium stearate.

Coating: Macrogol 6000; talc; hypromellose; titanium dioxide (E171); iron oxide red (E172).

Appearance of the product and contents of the package

Solifenacina Zentiva 10 mg are film-coated tablets, pink, biconvex, with a diameter of 10.0-10.2 mm.

Solifenacina Zentiva is supplied in blisters of 10, 30, 50, 90, and 100 film-coated tablets.

Only some package sizes may be marketed.

Marketing Authorization Holder

Zentiva, k.s.

U Kabelovny 130

102 37 Prague 10

Czech Republic

Manufacturers responsible

Saneca

Pharmaceuticals a.s.

Nitrianska 100

920 27 Hlohovec

Slovak Republic

For more information about this medication, please contact the local representative of the marketing authorization holder:

Zentiva Spain S.L.U.

Avenida de Europa, 19, Edificio 3, Planta 1.

28224 Pozuelo de Alarcón, Madrid

Spain

This medication is authorized in the member states of the European Economic Area with the following names:

Last review date of thisleaflet: December 2018

Other sources of information

The detailed information about this medication is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)